You Position: Home > Paper

Clinical study of irinotecan combined with suitable-symptom nutritional supporting treatment for advanced metastatic colorectal cancer

( views:239, downloads:16 )
Author:
No author available
Journal Title:
China Medicine
Issue:
10
DOI:
10.3760/cma.j.issn.1673-4777.2012.10.025
Key Word:
转移性结直肠癌;伊立替康;对症支持治疗;Advanced metastatic colorectal cancer;Irinotecan;Suitable-symptom nutritional support

Abstract: Objective To evaluate the clinical efficacy and the toxicity of irinotecan combined with suitable-symptom nutritional supporting treatment for patients with advanced metastatic colorectal cancer who were intolerant of chemotherapy.Methods Twenty-four patients with tumor node metastases(TNM)stage Ⅳ advanced metastatic colorectal cancer were enrolled,and their Karnofsky performance status(KPS)score was 40-60.The observation group had 13 cases and the control group was 11 cases.The observation group was treated by irinotecan and suitable-symptom nutritional support; the control group was treated by suitable-symptom nutritional support.Results Tumor response rate of patients was 15.4%(2/13)in the observation group; the disease control rate was 53.8%(7/13).Survival rate of 1-year in the observation group was higher than that in the control group [53.8(7/13)vs 27.3(3/11),P < 0.05]; KPS increasing rate was higher than that of the control group [53.8(7/13)vs 27.3(3/11),P < 0.05].Adverse chemotherapy reaction was tolerable.Conclusions Disease control rate and 1-year survival rate in the observation group are significantly higher than those in the control group in advanced metastatic colorectal cancer.It can improve life quality.Patient tolerance and compliance are satisfactory.

WanfangData CO.,Ltd All Rights Reserved
About WanfangData | Contact US
Healthcare Department, Fuxing Road NO.15, Haidian District Beijing, 100038 P.R.China
Tel:+86-010-58882616 Fax:+86-010-58882615 Email:yiyao@wanfangdata.com.cn